G.ST Antivirals is a clinical-stage biotech company that develops broad-spectrum antivirals against infections of the respiratory tract.
G.ST Antivirals has raised $6.7M in total funding. The most recent round was Series A. The last funding was announced in January 2024.
G.ST Antivirals's investors include Lansdowne Partners, xista science ventures.
G.ST Antivirals is headquartered in Vienna, Austria.
G.ST Antivirals is a clinical-stage biotech company that develops broad-spectrum antivirals against infections of the respiratory tract.
G.ST Antivirals is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"G.ST Antivirals — Funding & Investors." VCBacked, January 25, 2024, https://www.vcbacked.co/company/gst-antivirals. Accessed October 29, 2026.
VCBacked. (2024). G.ST Antivirals — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/gst-antivirals
{{cite web |title=G.ST Antivirals — Funding & Investors |url=https://www.vcbacked.co/company/gst-antivirals |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated